WT1 Peptide Immunotherapy for Cancer in Children and Young Adults
WT1 Peptide Immunotherapy for Cancer in Children and Young Adults
复制标题
DOI：
10.1002/pbc.22522
复制
发表时间：
2010-08-01
影响因子：
3.2
通讯作者：
Ozono, Keiichi
中科院分区：
文献类型：
--
作者：
Hashii, Yoshiko;Sato, Emiko;Ozono, Keiichi
肾母细胞瘤基因 (WT1) 在儿童癌症中可能过度表达。我们评估了 5 名患有实体癌或急性白血病的儿童接种 WT1 疫苗的效果。 WT1 疫苗被注射给 HLA-A*2402 阳性患者，这些患者尽管接受了常规治疗，但仍有 VVT1 过度表达的残留肿瘤。根据实体瘤疗效评价标准，1名患者显示完全缓解，1名患者病情稳定；其余三人表现出疾病进展。治疗相关的不良反应仅限于局部注射部位红斑。这些结果表明 WT1 疫苗接种具有治疗潜力，但在存在严重残留疾病的情况下，任何有益效果可能都不够。儿科血癌 2010；55：352-355。 (C) 2010 Wiley-Liss, Inc.
Wilms tumor gene (WT1) can be overexpressed in childhood cancers. We evaluated the efficacy of WT1 vaccination for five children with solid cancer or acute leukemia. WT1 vaccine was administered to HLA-A*2402-positive patients with VVT1-overexpressing residual tumor despite prior conventional treatment. One patient showed complete response and one patient showed stable disease according to the Response Evaluation Criteria in Solid Tumors; the remaining three showed progressive disease. Treatment-related adverse effects were limited to local injection site erythema. These results suggest that WT1 vaccination has therapeutic potential, but any beneficial effect may be insufficient in the presence of gross residual disease. Pediatr Blood Cancer 2010;55:352-355. (C) 2010 Wiley-Liss, Inc.